

Bowel Care in Palliative Care

Paul Daeninck, MD, MSc, FRCPC Palliative Medicine Consultant

Brenda Hearson, RN, MN, CHPCN(C)
Clinical Nurse Specialist



Objectives

Highlight Canadian Consensus Document on the Management of Constipation in Palliative Care (2010):

- normal bowel function
- factors leading to constipation
- preventive approach to constipation
- review best practice/approach

WRHA Algorithm for the Assessment and Management of Constipation in Palliative Care



Canadian Guideline Authors

Writing Committee:

S. Lawrence Librach, CCFP, FCFP Family Physician, Mt Sinai Hospital Professor, University of Toronto

Cindy Shobbrook, RN, MN, ACNP Advanced Practice Nurse, Princess Margaret Hospital, Toronto

Carlo DeAngelis, BPharm
Pharmacist, Odette Cancer Centre
Sunnybrook Health Sciences Centre, Toronto

Editorial Committee

Jean-Marc Bigonnesse, CCFP, FCFP Family Physician, Centre Hospitalier Universitaire de Sherbrooke

Paul Daeninck, FRCPC
Oncologist, Cancer Care Manitoba
Assistant Professor, University of Manitoba

Robin Fainsinger, CCFP, FCFP
Family Physician, Grey Nuns Community
Hospital and Health Centre
Director of Palliative Care Medicine, University of Alberta

David Henderson, CCFP, FCFP Family Physician, Colchester Regional Hospital, Truro, Nova Scotia

Ken Stakiw, CCFP, FCFP Family Physician, St. Paul's Hospital, Saskatoon



Normal Bowel Function


- Food moves through colon, water & electrolytes absorbed in the proximal region
- Waste products (i.e., stool) formed & stored in distal sigmoid colon
- Muscle contractions in colon propel the stool forward into the rectum
- When stool reaches rectum, most of the water absorbed



Normal Bowel Function

Coordinated effort:

- motility (peristalsis)
 - -intact myenteric plexus
 - -neurotransmitter &
 - -hormonal activity
- mucosal transport of fluids/electrolytes
- defecation reflex





Defining Constipation

- Unsatisfactory defecation
- Passage of small, dry, hard stools
- Painful passage (straining)
- Incomplete evacuation
- Bloating, abdominal distention
- Prolonged time to pass stool
- Need for manual maneuvers to pass stool
- Prolonged interval between BMs

(Normal range: 1 in 3 days to 3 in 1day)



General population:

12% - 19% of healthy adult population

Men: 8% Women: 21%

63% hospitalized elderly; 22% elderly at home

Palliative patients:

50% admitted to hospice (likely under estimate)

>60% require laxatives

~90% if on opioids (higher dose)



Etiology

Malignancy
Medications
Co-morbidities



Malignancy

Directly:


- Obstruction by tumour in bowel wall
- External compression by tumor
- Pelvic tumour invasion
 neural damage
 lumbar sacral spinal cord
 cauda equina/pelvic plexus
- Hypercalcemia, hypokalemia



Stage I



Stage II



Stage III





Malignancy

Complications of malignancy:

- poor oral intake
- dehydration
- low fibre intake
- weakness/inactivity
- medications



Medications

Anticholinergic activity

- phenothiazines
- tricyclic antidepressants
- antiparkinsonian agents
- scopolamine

Antacids

Anticonvulsants



Medications

Diuretics

Iron supplements

Antihypertensives

5-HT₃ antagonists

Chemotherapies

(Vinca alkaloids, Platinum agents, Taxanes)




Opioids and Constipation

Stomach

↓ gastric motility
Prolonged gastric emptying

Small intestine

- ↓ propulsive contractions
- ↓ fluid secretion
- † oral-cecal transit time Delayed digestion





Opioids and Constipation

Large intestine

Prolonged transit time


- ↓ propulsive peristalsis
- ↑ non-propulsive contractions

Increased desiccation of feces

† electrolyte & water absorption

Impaired defecation reflex

- ↓ sensitivity to distension
- ↑ internal anal sphincter tone
- ↓ reflex relaxation response





Co-morbidities

Hypothyroidism

Hernia

Anal fissure

Hemorrhoids

Diverticular disease

Colitis

Metabolic

hypercalcemia

hypokalemia

Autonomic neuropathy

diabetes

spinal cord disease

chemotherapy

Parkinson's disease

ALS/MS

Dementia

Renal Failure - Uremia



Other Predisposing Factors

Confusion

Depression

Unfamiliar toilet arrangements

Lack of privacy



Complications of Constipation

Increased pain / colic

Nausea / vomiting

"Diarrhea" / fecal incontinence (stool overflow)

Dyspepsia / heartburn

Impaired GI absorption (including meds)

Urinary retention

Encephalopathy (delirium)



Overall Impact of Constipation

Poor quality of life

- Dignity
- Depression

Stress for caregivers, family

Added burden for health care providers

Added cost for care

- Longer hospital stays
- Increased medication use



Assessment

Patient History

- Initial questions
- Common complaints
- Other considerations/Quality of Life

Physical Examination

Diagnostic Tests



Initial Questions

When was your last satisfactory BM?

What is your previous BM frequency?

What is the colour and consistency of the stool?

Do you have a feeling of incomplete evacuation or a need to strain?

Are you passing gas?

Medication history including laxative use?

Previous need for manual disimpaction/enemas?

Other symptoms?:

- -nausea/vomiting
- -localized pain
- -decreased appetite/early satiety



Common Indicators

- Generalized malaise secondary to constipation
- Alternating constipation and diarrhea
- Complaints of overflow diarrhea/incontinence (more common in elderly; lower abdominal cancers)
- May have bleeding secondary to anal fissures or hemorrhoids



Other Considerations

- What is the food, fibre and fluid intake?
- Activity level?
- Need for a bedpan or commode? Privacy?
- Are other ADLs affected?
- Associated psychological distress or decreased socialization?



Victoria Bowel Performance Scale

- 4	- 3	- 2	-1	BPS Score 0
← Constipation				Normal
Impacted or Obstructed +/- small leakage	Formed Hard with pellets	Formed Hard	Formed Solid	Characteristics
				Formed Semi-solid
	₹,	CERRE	SEE	CHP (
No stool produced	Delayed ≥ 3 days	Delayed ≥ 3 days	Patient's Usual	Pattern
				Patient's Usual
Unable to defecate despite maximum effort or straining	Major effort or strain- ing required to defecate	Moderate effort or strain- ing required to defecate	Minimal or no effort required to defecate	Control
				Minimal or no ef- fort to defecate



Physical Examination

Physical Appearance

Volume Status, dehydration, cachexia

Abdominal exam

Localized tenderness, abdominal distention, fecal mass Fecal versus tumour masses Bowel sounds (hypo/hyperactive)

Anorectal inspection Fissures, hemorrhoids, anal leakage

Digital rectal exam

Full or empty rectum, stool consistency



Signs of a possible bowel obstruction:

- Marked distention
- Lack of bowel sounds
- No passing of gas

Notify the clinician for immediate action



Investigations


Abdominal X-ray (2 views)

Blood work (Ca, K, TSH)

Specialized imaging*

Measurements of transit time*







Management

Principles:

- Preventive approach vs. crisis intervention
- Correct reversible causes
- Early intervention
- Educate patient, family and health care team
- Set realistic expectations for patient and family
- Monitor effectively
- Interdisciplinary team approach for assessment and evaluation



Management

Prevention:

- good symptom control
- encourage activity within limitations
- adequate hydration as able
- recognize drug effect
- assess fibre content in diet
- create a favorable environment



Laxatives for the management of constipation in palliative care patients (Review)

Miles C, Fellowes D, Goodman ML, Wilkinson SSM



Cochrane Review 2006

- Treatment of constipation in palliative care is not based on adequate data from randomized controlled trials
- Poor data on use of laxatives individually, in combination or sequentially
- All the laxatives used in the trials were ineffective in large numbers of patients
- High use of rescue laxatives
- Multiple rescue episodes per patient



Cochrane Review 2006

Adverse effects from laxatives are poorly reported

"There persists an uncertainty about the 'best' management of constipation in this group of patients"

Recommend:

"Laxative prescribing must follow an identified protocol with 'very' regular monitoring and titration of management in response to individual patient response"



WRHA Palliative Care Program Algorithm

Draft form as circulated

Requires final approval and roll-out across the settings of our program

Adapted from:

- -European guidelines (Larkin et al 2008. *Pall Medicine*, 22: 796-807) and
- -Canadian Consensus Document (Librach et al 2010 JPSM, 40: 761-773)




WRHA Palliative Care Program Constipation Assessment & Management Algorithm

Prevention:

- >Anticipate constipating effects of pharmacological agents such as opioids and prescribe laxative prophylactically (e.g., daily senna)
- Monitor bowel pattern and patient satisfaction with bowel function
- Monitor risk factors for constipation

Patient/family education and preventative strategies:

- Increase fluid intake and natural agents found effective by patient (e.g. prunes/juice)
- Encourage mobility/activity if possible
- Avoid insoluble fibre (bulk-forming agents, e.g. Psyllium) if limited fluid intake/activity
- Ensure privacy, comfort, and sitting position to allow a patient to defecate normally






WRHA Palliative Care Program Constipation Assessment & Management Algorithm

Prevention:

- Anticipate constipating effects of pharmacological agents such as opioids and prescribe laxative prophylactically (e.g., daily senna)
- Monitor bowel pattern and patient satisfaction with bowel function
- ➤ Monitor risk factors for constipation

Patient/family education and preventative strategies:

- Increase fluid intake and natural agents found effective by patient (e.g. prunes/juice)
- Encourage mobility/activity if possible
- Avoid insoluble fibre (bulk-forming agents, e.g. Psyllium) if limited fluid intake/activity
- Ensure privacy, comfort, and sitting position to allow a patient to defecate normally





Medication Table - General Guidelines for Bowel Care

Laxative	Usual Dose range	Comments
Stimulant laxatives		
Senna glycosides	8.6 – 68.8mg	Recommended as 1 st line
(ex: Senokot®)	1-8 tabs/day	
Osmotic laxatives		
Lactulose	15-30 ml OD – QID	
PEG 3350 (MiraLAX®, LaxADay™)	17-34g OD - TID	Recommended as 1 st line
Suppositories		
Bisacodyl, Glycerin	Give together Q72h	
Enemas		
Phosphate	Max 1 in 24H	Risk of electrolyte disturbance
Saline		with phosphate/saline
Mineral Oil	Q72H prn	
Selective Opioid Receptor Blocker		For refractory Opioid Induced
Methylnaltrexone	8 – 12 mg Subcut	Constipation
Stool Softeners		Do not use without stimulant
Docusate	100 – 200 mg OD	laxative
Fibre		Not Recommended in
Psyllium		Palliative Care



Laxatives: Osmotic Laxatives

Function by increasing fluid retention in stool (grade A):

- Lactulose (30 to 120 mL daily)
- PEG 3350 (MiraLAX[®] / Lax-A-Day[®], 17g OD-BID)
- Polyethylene glycol (4 L 250 mL q 10-30 mins)
- Magnesium hydroxide (15-60 mL daily)
- Insufficient data for chronic constipation (grade B)



Cochrane Review 2010: Lactulose vs PEG

Lactulose versus Polyethylene Glycol for Chronic Constipation (Review)

Lee-Robichaud H, Thomas K, Morgan J, Nelson RL



Cochrane Review 2010: Lactulose vs PEG

Conclusion:

Among patients with chronic constipation PEG 3350 clearly superior based on:

- Frequency of BM's
- Relief of pain
- Need for extra medications
- But more costly \$0.72 vs \$0.48 /dose



Laxatives: Stimulants

Irritate sensory nerve endings, increasing muscle contractions, reduce water absorption (e.g. Bisacodyl, Sennosides):

- Mainstay regimen in advanced illness (grade B)
- Insufficient data for recommendation with chronic constipation
- Large doses often needed for efficacy (6-10 tablets per day)



Laxatives: Softners / Wetting Agents

Docusate commonly prescribed in advanced illness despite lack of evidence

- Insufficient data for recommendation with chronic constipation (grade B)
- Stool softeners likely inferior to psyllium for chronic constipation (grade B)



Laxatives: Softners / Wetting Agents

JOURNAL OF PALLIATIVE MEDICINE Volume 11, Number 4, 2008 © Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2007.0178

A Comparison of Sennosides-Based Bowel Protocols with and without Docusate in Hospitalized Patients with Cancer

PHILIPPA HELEN HAWLEY, B.Med., FRCPC1 and JAI JUN BYEON, M.D., Ph.D.2

Conclusions: The addition of the initial docusate-only step and adding docusate 400–600 mg/d to the sennosides did not reduce bowel cramps, and was less effective in inducing laxation than the sennosides-only protocol. Further research into the appropriate use of docusate and into the details of bowel protocol design are required.



Laxatives: Lubricants & Herbals

- Insufficient data to make a recommendation (grade C)
- Mineral oil, herbal teas (with senna) commonly used
- May interfere with absorption of fat soluble vitamins, medications



- Psyllium increases stool frequency (grade B)
- Calcium polycarbophil, methylcellulose and bran (grade B)
- Require > 1.5 L/day fluid intake

NOT recommended in palliative care for patients taking opioids



Laxatives: Saline Cathartics

Magnesium citrate, oral sodium phosphate (oral Fleet) commonly used, but evidence is lacking



Other Options

Enemas/suppositories if constipation is established and no BM for 3+ days:

Sodium phosphate enema to start

small volume and work best if stool in rectum

Large volume saline or water

- administered only by experienced care providers
- should never be used if bowel strictures, recent bowel surgery or any bowel obstruction



Other Options

Disimpaction

- Rarely used but may be necessary if stool is hard and impacted
- Use oil enema prior to procedure and local anesthetic gel if necessary
- Some pts may require sedation prior to procedure




Other Approaches

- Prokinetic agents: domperidone, metoclopramide
- Antibiotics: erythromycin
- Fruit mixtures: prunes, dates, papaya, raisins, figs
- Herbal preparations: mulberry, licorice root



Newer Approaches



Methylnaltrexone: a selective peripheral antagonist without central effects Methylnaltrexone (MNTX, Relistor™):

Indicated for the treatment of opioidinduced constipation in patients with advanced illness, receiving palliative care Currently subcutaneous route only



Summary Pearls

- Constipation is common
- Multiple causes in the palliative patient
- Prevention important (opioid R + laxative R)
- Assessment key (don't forget the DRE!)
- Follow the algorithm



Questions & Discussion

Paul Daeninck, MD, MSc, FRCPC Palliative Medicine Consultant paul.daeninck@cancercare.mb.ca

Brenda Hearson, RN, MN, CHPCN(C) Clinical Nurse Specialist bhearson@wrha.mb.ca